表紙
市場調査レポート

免疫治療薬の世界市場:疫学・法規制・パイプラインの分析および市場予測 〜2020年:モノクローナル抗体・インターフェロンα・インターロイキン・治療&予防ワクチン・チェックポイント阻害剤

Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 346465
出版日 ページ情報 英文 127 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
免疫治療薬の世界市場:疫学・法規制・パイプラインの分析および市場予測 〜2020年:モノクローナル抗体・インターフェロンα・インターロイキン・治療&予防ワクチン・チェックポイント阻害剤 Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020
出版日: 2015年12月01日 ページ情報: 英文 127 Pages
概要

当レポートでは、世界の免疫治療薬の市場について調査し、癌の発症数・死亡数・5年有病数の推計、主要国の薬価設定・償還環境、パイプラインの状況、現在の治療プロトコル・治療の選択、免疫治療薬市場の成長推進因子・阻害因子および市場機会の分析、薬剤タイプ・地域/国別の主要動向および市場規模の推移と予測、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 免疫治療薬の成長の見通し
  • 世界市場の規模
  • 地域概要
  • 薬剤タイプ別
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 産業分析

  • 癌の疫学
    • 発症数・死亡数・5年有病数の推計:男性
    • 発症数・死亡数・5年有病数の推計:女性
    • 発症数・死亡数・5年有病数の推計:総計
  • 薬価設定・償還
    • 米国
    • 英国
    • フランス
    • ドイツ
    • その他の欧州諸国
    • 日本
  • パイプライン
    • 第I相
    • 第I/II相
    • 第II相
    • 第II/III相
    • 第III相
    • 申請済み
  • 確実視される分子
  • 治療プロトコル・治療の選択
    • 第一選択療法
    • 第二選択療法
    • その他

第7章 市場分析:薬剤タイプ別

  • イントロダクション
  • モノクローナル抗体
  • インターフェロン
  • インターロイキン
  • ワクチン
  • チェックポイント阻害薬

第8章 地域分析

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
  • その他

第9章 競合環境

  • 概要
  • 市場シェア分析
  • 競合状況・動向
    • 承認
    • 合意・提携・協力
    • 買収

第10章 企業概要

  • イントロダクション
  • F. HOFFMANN-LA ROCHE AG
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • GLAXOSMITHKLINE PLC
  • AMGEN INC.
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND COMPANY
  • CELGENE CORPORATION
  • SEATTLE GENETICS, INC.
  • SPECTRUM PHARMACEUTICALS, INC.
    • 財務動向
    • 製品・サービス
    • 戦略
    • 発展動向、など

第11章 付録

図表

目次
Product Code: PH 3926

The immunotherapy drugs market is broadly segmented on the basis of type of drugs and geographic region. The major type of immunotherapy drugs studied in the report includes antibodies (monoclonal and polyclonal), interferon (alpha), interleukins, vaccines, and checkpoint inhibitors. Among these types of drugs, monoclonal antibodies segment is expected to command the largest share while checkpoint inhibitors is expected to grow at the highest rate. This high growth rate is attributed to the technological advancement and higher efficacy of checkpoint inhibitors.

The immunotherapy drugs market, by geography, is classified into North America, Europe, Asia-Pacific, and Rest of the World. The North American geographic segment will account for the largest share of the global immunotherapy drugs market in 2015, followed by the Europe geographic segments. The Asia-Pacific segment is expected to account for highest CAGR of the immunotherapy drugs market in 2015. The major drivers for the growth of this market are increasing incidence of different types of cancer; focus on targeted therapies with fewer side effects and quicker drug approval processes.

From an insight perspective, this research report focuses on qualitative data, market size, growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market sizes and data of various segments in this industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives by governments. The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on the key players in the immunotherapy drugs market and the strategies adopted by them to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of the future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report analyzes the immunotherapy drugs market by technology, application, products & services, and end user
  • Product Development/Innovation: Detailed insights on upcoming technologies and R&D activities in the immunotherapy drugs market
  • Competitive Assessment: In-depth assessment of market strategies, geographic and business segments, and product portfolios of leading players in the immunotherapy drugs market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various products across geographies
  • Market Diversification: Exhaustive information on new products and services, untapped geographies, recent developments, and investments in the immunotherapy drugs market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
      • 2.2.2.1. Key industry insights
    • 2.2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. IMMUNOTHERAPY DRUGS MARKET TO GROW AT A RAPID RATE
  • 4.2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET
  • 4.4. IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG
  • 4.5. LIFECYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. INCREASING ADOPTION OF TARGETED THERAPY OVER TRADITIONAL THERAPY
    • 5.4.2. REDUCTION IN OVERALL TIMELINE AND COST FOR DRUG DISCOVERY
    • 5.4.3. HIGH PREVALENCE RATE OF LIFESTYLE DISEASES
    • 5.4.4. FAST TRACK AND ORPHAN DRUG DESIGNATIONS
  • 5.5. RESTRAINTS
    • 5.5.1. HIGH COST OF IMMUNOTHERAPY TREATMENT
    • 5.5.2. HIGH ATTRITION RATE IN THE PRODUCT DEVELOPMENT CYCLE
  • 5.6. OPPORTUNITIES
    • 5.6.1. SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES
    • 5.6.2. IMMUNOTHERAPY TO REPLACE CHEMOTHERAPY AS A FIRST-LINE THERAPY
  • 5.7. CHALLENGES
    • 5.7.1. PATENT EXPIRIES OF TOP-SELLING BIOLOGICS

6. CANCER IMMUNOTHERAPY MARKET- INDUSTRY INSIGHTS

  • 6.1. CANCER EPIDEMIOLOGY
    • 6.1.1. ESTIMATED INCIDENCE, MORTALITY, AND 5-YEAR PREVALENCE: MEN (2012)
    • 6.1.2. ESTIMATED INCIDENCE, MORTALITY, AND 5-YEAR PREVALENCE: WOMEN
    • 6.1.3. ESTIMATED INCIDENCE, MORTALITY, AND 5-YEAR PREVALENCE: BOTH SEXES (2012)
  • 6.2. PRICING AND REIMBURSEMENT
    • 6.2.1. U.S.
    • 6.2.2. U.K.
    • 6.2.3. FRANCE
    • 6.2.4. GERMANY
    • 6.2.5. OTHER EUROPEAN COUNTRIES
    • 6.2.6. JAPAN
  • 6.3. PIPELINE
    • 6.3.1. PHASE 1
    • 6.3.2. PHASE I/II
    • 6.3.3. PHASE II
    • 6.3.4. PHASE II/III
    • 6.3.5. PHASE III
    • 6.3.6. APPLICATION SUBMITTED
  • 6.4. PROMISING MOLECULES
  • 6.5. TREATMENT PROTOCOLS AND LINE OF THERAPIES
    • 6.5.1. FIRST LINE THERAPY
    • 6.5.2. SECOND LINE THERAPY
    • 6.5.3. OTHER TREATMENTS

7. IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUGS

  • 7.1. INTRODUCTION
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. INTERFERONS
  • 7.4. INTERLEUKINS
  • 7.5. VACCINES
  • 7.6. CHECKPOINT INHIBITORS

8. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. NORTH AMERICA
    • 8.2.1. U.S.
    • 8.2.2. CANADA
  • 8.3. EUROPE
    • 8.3.1. GERMANY
    • 8.3.2. U.K.
    • 8.3.3. FRANCE
    • 8.3.4. ITALY
    • 8.3.5. SPAIN
  • 8.4. ASIA-PACIFIC
    • 8.4.1. JAPAN
    • 8.4.2. CHINA
    • 8.4.3. INDIA
  • 8.5. REST OF THE WORLD (ROW)

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. MARKET SHARE ANALYSIS
  • 9.3. COMPETITIVE SITUATION AND TRENDS
    • 9.3.1. APPROVALS
    • 9.3.2. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 9.3.3. ACQUSITIONS

10. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 10.1. INTRODUCTION
  • 10.2. F. HOFFMANN-LA ROCHE AG
  • 10.3. MERCK & CO., INC.
  • 10.4. NOVARTIS INTERNATIONAL AG
  • 10.5. GLAXOSMITHKLINE PLC
  • 10.6. AMGEN INC.
  • 10.7. BRISTOL-MYERS SQUIBB
  • 10.8. ELI LILLY AND COMPANY
  • 10.9. CELGENE CORPORATION
  • 10.10. SEATTLE GENETICS, INC.
  • 10.11. SPECTRUM PHARMACEUTICALS, INC.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

11. APPENDIX

  • 11.1. INSIGHTS OF INDUSTRY EXPERTS
  • 11.2. DISCUSSION GUIDE
  • 11.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 11.4. AVAILABLE CUSTOMIZATIONS
  • 11.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 2: GLOBAL MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 3: NORTH AMERICA: MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 4: EUROPE: MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 5: ASIA-PACIFIC: MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 6: GLOBAL INTERFERON DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 7: NORTH AMERICA: INTERFERON DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 8: EUROPE: INTERFERON DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 9: ASIA-PACIFIC: INTERFERON DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 10: GLOBAL INTERLEUKIN DRUGS MARKET SIZE, 2013-2020 (USD MILLION)
  • TABLE 11: GLOBAL VACCINES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 12: GLOBAL VACCINES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 13: NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 14: EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 15: ASIA-PACIFIC: VACCINES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 16: GLOBAL CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 17: NORTH AMERICA: CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 18: EUROPE: CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 19: ASIA-PACIFIC: CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 20: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 21: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 22: U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 23: CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 24: EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 25: GERMANY: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 26: U.K.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 27: FRANCE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 28: ITALY: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 29: SPAIN: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 30: APAC: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 31: JAPAN: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 32: CHINA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 33: INDIA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 34: ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • TABLE 35: APPROVALS, 2013-2015
  • TABLE 36: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013-2015
  • TABLE 37: ACQUSITIONS, 2013-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN: IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 2: MARKET SIZE ESTIMATION
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: DATA TRIANGULATION METHODOLOGY
  • FIGURE 5: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT (2015 VS. 2020): CHECKPOINT INHIBITORS WILL GROW AT THE HIGHEST RATE IN THE NEXT FIVE YEARS
  • FIGURE 6: GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG, 2015
  • FIGURE 7: GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE, 2015
  • FIGURE 8: CHANGING DEMOGRAHICS AND FOCUS ON TARGETED THERAPIES TO DRIVE MARKET GROWTH
  • FIGURE 9: MONOCLONAL ANTIBODIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET IN 2015
  • FIGURE 10: APAC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 11: CHECKPOINT INHIBITORS EXPECTED TO BE THE FASTEST GROWING SEGMENT
  • FIGURE 12: NORTH AMERICA AND APAC MARKETS HOLD LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 13: MARKET SEGMENTATION
  • FIGURE 14: GLOBAL IMMUNOTHERAPY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
  • FIGURE 15: MONOCLONAL ANTIBODIES SEGMENT IS EXPECTED TO DOMINATE THE MARKET IN 2015
  • FIGURE 16: INTERFERON DRUGS MARKET IN APAC TO WITNESS HIGHEST GROWTH FROM 2015 TO 2020
  • FIGURE 17: THERAPEUTIC VACCINES TO WITNESS HIGHER GROWTH IN THE FORECAST PERIOD
  • FIGURE 18: NORTH AMERICA TO WITNESS HIGHEST GROWTH IN THE CHECKPOINT INHIBITORS MARKET FROM 2015 TO 2020
  • FIGURE 19: GEOGRAPHIC SNAPSHOT (2015): ASIA-PACIFIC WILL BE THE FASTEST-GROWING REGION BY 2020
  • FIGURE 20: NORTH AMERICA, AN ATTRACTIVE DESTINATION FOR MONOCLONAL ANTIBODIES AND CHECKPOINT INHIBITORS
  • FIGURE 21: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 22: THE CHECKPOINT INHIBITORS SEGMENT IS THE FASTEST-GROWING MARKET SEGMENT IN THE U.S.
  • FIGURE 23: THE MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE THE IMMUNOTHERAPY DRUGS MARKET IN EUROPE DURING THE FORECAST PERIOD
  • FIGURE 24: APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 25: THE INCREASING NUMBER OF KEY MARKET PLAYERS FOCUSING ON LATIN AMERICAN COUNTRIES IS DRIVING THE IMMUNOTHERAPY DRUGS MARKET IN THE ROW REGION 91  
  • FIGURE 26: COMPANIES ADOPTED NEW PRODUCT LAUNCHES AND APPROVALS AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS
  • FIGURE 27: GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
  • FIGURE 28: BATTLE FOR MARKET SHARE: APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2015
  • FIGURE 29: GEOGRAPHIC REVENUE MIX OF THE TOP FOUR MARKET PLAYERS
Back to Top